From Logic-Respecting Efficacy Estimands to Logic-Ensuring Analysis Principle for Time-to-Event Endpoint in Randomized Clinical Trials with Subgroups

References

• Benichou, J., and Gail, M. H. (1989), “A Delta Method for Implicitly Defined Random Variables,” The American Statistician, 43, 41–44. DOI: 10.2307/2685169.
   Web of Science ®Google Scholar
• Chatfield, C. (1995), “Model Uncertainty, Data Mining and Statistical Inference,” Journal of the Royal Statistical Society, Series A, 158, 419–466. DOI: 10.2307/2983440.
   Web of Science ®Google Scholar
• Chen, Z., and Zhang, G. (2016), “Comparing Survival Curves based on Medians,” BMC Medical Research Methodology, 16, 1–7. DOI: 10.1186/s12874-016-0133-3.
   PubMedGoogle Scholar
• Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G., and Piccart, M. J. (2015), “A Standardised, Generic, Validated Approach to Stratify the Magnitude of Clinical Benefit that can be Anticipated from Anti-cancer Therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (esmo-mcbs),” Annals of Oncology, 26, 1547–1573. DOI: 10.1093/annonc/mdv249.
   PubMed Web of Science ®Google Scholar
• Cherny, N., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E., and Piccart, M. (2017), “A Standardised, Generic, Validated Approach to Stratify the Magnitude of Clinical Benefit that can be Anticipated from Anti-cancer Therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (esmo-mcbs),” Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28, 2901–2905. DOI: 10.1093/annonc/mdw258.
   PubMed Web of Science ®Google Scholar
• Copas, J. B., and Long, T. (1991), “Estimating the Residual Variance in Orthogonal Regression with Variable Selection,” Journal of the Royal Statistical Society, Series D, 40, 51–59. DOI: 10.2307/2348223.
   Google Scholar
• Daniel, R., Zhang, J., and Farewell, D. (2021), “Making Apples from Oranges: Comparing Noncollapsible Effect Estimators and their Standard Errors after Adjustment for Different Covariate Sets,” Biometrical Journal, 63, 528–557. DOI: 10.1002/bimj.201900297.
   PubMed Web of Science ®Google Scholar
• Derksen, S., and Keselman, H. J. (1992), “Backward, Forward and Stepwise Automated Subset Selection Algorithms: Frequency of Obtaining Authentic and Noise Variables,” British Journal of Mathematical and Statistical Psychology, 45, 265–282. DOI: 10.1111/j.2044-8317.1992.tb00992.x.
   Web of Science ®Google Scholar
• Ding, Y., Lin, H.-M., and Hsu, J. C. (2016), “Subgroup Mixable Inference on Treatment Efficacy in Mixture Populations, with an Application to Time-to-Event Outcomes,” Statistics in Medicine, 35, 1580–1594. DOI: 10.1002/sim.6822.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (2020), “International Council of Harmonization (ICH) E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” Available at https://www.ich.org.
   Google Scholar
• Food and Drug Administration (2021), “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products,” available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products.
   Google Scholar
• Gadgeel, S., Rodriguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Domine, M., et al. (2020), “Updated Analysis from Keynote-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, 38, 1505–1517. DOI: 10.1200/JCO.19.03136.
   PubMed Web of Science ®Google Scholar
• Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018), “Blood-based Tumor Mutational Burden as a Predictor of Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Atezolizumab,” Nature Medicine, 24, 1441–1448. DOI: 10.1038/s41591-018-0134-3.
   PubMed Web of Science ®Google Scholar
• Greenland, S., Pearl, J., and Robins, J. M. (1999), “Confounding and Collapsibility in Causal Inference,” Statistical Science, 14, 29–46. DOI: 10.1214/ss/1009211805.
   Web of Science ®Google Scholar
• Guyot, P., Ades, A., Ouwens, M. J., and Welton, N. J. (2012), “Enhanced Secondary Analysis of Survival Data: Reconstructing the Data from Published Kaplan-Meier Survival Curves,” BMC Medical Research Methodology, 12, 1–13. DOI: 10.1186/1471-2288-12-9.
   PubMedGoogle Scholar
• Harrel, F. E. (2015), Regression Modeling Strategies (Vol. 608), Cham: Springer.
   Google Scholar
• Hernán, M. A., and Robins, J. M. (2020), Causal Inference: What If, Boca Raton, FL: Chapman & Hall/CRC.
   Google Scholar
• Huitfeldt, A., Stensrud, M. J., and Suzuki, E. (2019), “On the Collasibility of Measures of Effect in the Counterfactual Causal Framework,” Emerging Themes in Epidemiology, 16. DOI: 10.1186/s12982-018-0083-9.
   PubMed Web of Science ®Google Scholar
• Kalbfleisch, J. D., and Prentice, R. L. (2002), The Statistical Analysis of Failure Time Data (Vol. 360), Hoboken, NJ: Wiley.
   Google Scholar
• Kent, D. M., Paulus, J. K., Van Klaveren, D., D’Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P., Patrick-Lake, B., Morton, S., Pencina, M., et al. (2020), “The Predictive Approaches to Treatment Effect Heterogeneity (path) Statement,” Annals of Internal Medicine, 172, 35–45. DOI: 10.7326/M18-3667.
   PubMed Web of Science ®Google Scholar
• Li, Y., and Zhang, Q. (2015), “A Weibull Multi-State Model for the Dependence of Progression-Free Survival and Overall Survival,” Statistics in Medicine, 34, 2497–2513. DOI: 10.1002/sim.6501.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Wang, B., Yang, M., Hui, J., Xu, H., Kil, S., and Hsu, J. C. (2020), “Correct and Logical Causal Inference for Binary and Time-to-Event Outcomes in Randomized Controlled Trials,” Biometrical Journal, 64, 198–224. DOI: 10.1002/bimj.202000202.
   Web of Science ®Google Scholar
• Miltenberger, R., Götte, H., Schüler, A., and Jahn-Eimermacher, A. (2021), “Progression-Free Survival in Oncological Clinical Studies: Assessment Time Bias and Methods for its Correction,” Pharmaceutical Statistics, 20, 864–878. DOI: 10.1002/pst.2115.
   PubMed Web of Science ®Google Scholar
• Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021), “First-Line Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (checkmate 9la): An International, Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology, 22, 198–211. DOI: 10.1016/S1470-2045(20)30641-0.
   PubMed Web of Science ®Google Scholar
• Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020), “Pembrolizumab Plus Axitinib versus Sunitinib Monotherapy as First-Line Treatment of Advanced Renal Cell Carcinoma (keynote-426): Extended Follow-up from a Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology, 21, 1563–1573. DOI: 10.1016/S1470-2045(20)30436-8.
   PubMed Web of Science ®Google Scholar
• Reid, N. (1994), “A Conversation with Sir David Cox,” Statistical Science, 9, 439–455. DOI: 10.1214/ss/1177010394.
   Web of Science ®Google Scholar
• Royston, P., and Parmar, M. K. (2013), “Restricted Mean Survival Time: An Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials with a Time-to-Event Outcome,” BMC Medical Research Methodology, 13, 1–15. DOI: 10.1186/1471-2288-13-152.
   PubMed Web of Science ®Google Scholar
• Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016), “Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received,” Journal of Clinical Oncology, 34, 2925–2934. DOI: 10.1200/JCO.2016.68.2518.
   PubMed Web of Science ®Google Scholar
• Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015), “American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options,” Journal of Clinical Oncology, 33, 2563–2577. DOI: 10.1200/JCO.2015.61.6706.
   PubMed Web of Science ®Google Scholar
• Wey, A., Connett, J., and Rudser, K. (2015), “Combining Parametric, Semi-parametric, and Non-parametric Survival Models with Stacked Survival Models,” Biostatistics, 16, 537–549. DOI: 10.1093/biostatistics/kxv001.
   PubMed Web of Science ®Google Scholar
• Xi, D., and Bretz, F. (2022), “Discussion on ‘Correct and Logical Causal Inference for Binary and Time-to-Event Outcomes in Randomized Controlled Trials’,” Biometrical Journal, 64, 243–245. DOI: 10.1002/bimj.202100060.
   PubMed Web of Science ®Google Scholar
• Xu, R., and O’Quigley, J. (2000), “Estimating Average Regression Effect under Non-Proportional Hazards,” Biostatistics, 1, 423–439. DOI: 10.1093/biostatistics/1.4.423.
   PubMedGoogle Scholar
• Zhao, L., Claggett, B., Tian, L., Uno, H., Pfeffer, M. A., Solomon, S. D., Trippa, L., and Wei, L. (2016), “On the Restricted Mean Survival Time Curve in Survival Analysis,” Biometrics, 72, 215–221. DOI: 10.1111/biom.12384.
   PubMed Web of Science ®Google Scholar